Dorsey Wright & Associates 89bio, Inc. Transaction History

Dorsey Wright & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$15.06 - $19.41 $1,460 - $1,882	-97 Reduced 3.34%	2,803 $43,000
Q2 2023 Jul 26, 2023	BUY	$14.15 - $22.03 $4,117 - $6,410	291 Added 11.15%	2,900 $54,000
Q1 2023 Apr 19, 2023	SELL	$10.48 - $16.94 $3,049 - $4,929	-291 Reduced 10.03%	2,609 $39,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $16,007 - $36,917	2,900 New	2,900 $36,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.